Ophthalmic Drug Delivery: Meeting Modern Challenges With A Next Generation Solution

By Abigail Hisler

Ophthalmic injectables are among the most technically demanding drug delivery formats, and the packaging decisions you make early in development can have serious downstream consequences. The intravitreal market is expanding fast: nearly 70 pipeline programs are currently in development, double the count from 2015, with market volumes projected to grow 7% between 2026 and 2029. Biosimilars are adding further competitive pressure.

But growth brings complexity. Silicone oil contamination, particulate control, endotoxin limits, and dosing accuracy are all live risks in this space, and regulators are not making it easier. Standards like USP <789>, FDA's 0.2 EU/device endotoxin guidance for intraocular devices, and EP 5.1.10 set acceptance criteria that are notably stricter than those for conventional parenterals. Standard syringe and plunger designs were not built to meet these thresholds.

The core argument here is straightforward: if you treat packaging as a late-stage decision, you're accepting preventable risk. Contamination or dosing errors in ophthalmic injectables aren't just regulatory problems; they can cause inflammation or permanent vision loss. Getting the right container-closure system in place from the start is not a nice-to-have. Access the full analysis to understand which regulatory requirements apply to your program and where conventional packaging typically falls short.